Jeffrey D. Isaacson

TL;DR: Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation and the only common dose-limiting adverse event was hyperglycemia.

TL;DR: The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC).

TL;DR: Targeted next-generation sequencing of circulating cell-free DNA extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib found BRCa reversion mutations detected in cfDNA from platinum-resistant or platinum-refractory HGOC.

TL;DR: Lucitanib has promising efficacy and a manageable side-effect profile, and the spectrum of activity observed demonstrates clinical benefit in both FGF-aberrant and angiogenesis-sensitive populations.

TL;DR: Adverse events were consistent with atrasentan's pharmacologic vasodilatory effect, and linear, dose-proportional pharmacokinetics suggest that atrasents can be easily and consistently dosed.